Inclusion Criteria:

• Willing and able to provide written informed consent.
• Age ≥ 18 years.
• Diagnostic coronary angiography or percutaneous coronary intervention via the transradial approach.

Exclusion Criteria:

• Individuals < 18 years old.
• Presence of a palpable hematoma or clinical concern of hemostasis at the transradial access site
• Access or attempted access at a second site – including contralateral radial artery, brachial, or femoral artery or vein
• Planned staged procedure, CABG or noncardiac surgery within 30 days
• Contraindication or high risk of bleeding with anticoagulation:
  • bleeding requiring medical attention in the previous 6 months;
  • thrombocytopenia (platelets < 50 x 10^9/L);
  • prior intracranial hemorrhage;
  • use of IIb/IIIa during percutaneous coronary intervention;
  • administration of thrombolytic therapy in the preceding 24 hours;
  • use of non-steroidal anti-inflammatory medications;
  • ischemic stroke or transient ischemic attack diagnosed in the last 3 months.
• Cardiogenic shock.
• Ventricular arrhythmias refractory to treatment.
• Liver dysfunction (Child-Pugh class B or C).
• Unexplained anemia with a Hgb below 100 g/L.
• History of medication noncompliance or risk factor for noncompliance.
• Active malignancy.
• Allergy to rivaroxaban.
• Another indication for anticoagulation.
• CYP3A4 and P-glycoprotein inhibitor use.
• Life expectancy < 30 days.
• Women capable of pregnancy not on birth control.
• Chronic kidney disease with creatinine clearance of less than 30mL/min.
• History of antiphospholipid syndrome, in particular triple positive (lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies).